Archivos del autor: Erika Erdmann

OPKO to Discuss Draft Coverage Determinations for 4Kscore® Test at 2016 Jefferies Healthcare Conference

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO’s 4Kscore® test at the Jefferies Healthcare Conference in New York City on jueves, 9 de junio de 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA […]

OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore® Test

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) (“OPKO” or the “Company”) announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New […]

OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announces the appointment of Gregory Henderson, M.D., Ph.D., as President of BioReference Laboratories (BRL), effective immediately. Dr. Henderson succeeds Marc Grodman, M.D., who is resigning, having served as Chairman, President and CEO of BRL since founding the company in 1981. OPKO acquired BRL in August 2015. Dr. Grodman […]

OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced the decision of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel to include the 4Kscore® Test in the 2016 EAU Guidelines for Prostate Cancer. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first prostate biopsy […]

OPKO’s GeneDx Presenting on a Number of Topics at the 2016 ACMG Annual Clinical Genetics Meeting

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. announced today that its GeneDx subsidiary and business unit has been selected to give 11 platform talks and 18 poster presentations on a range of genetics-related topics at the 2016 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. These presentations support GeneDx’s position as an industry leader in the wider genomics industry. […]

OPKO’s GeneDx Participating in the Molecular Medicine Tri-Conference 2016 in San Francisco

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announced today that GeneDx was invited to participate in the Molecular Medicine Tri-Conference 2016, being held at the Moscone North Convention Center in San Francisco, California from March 6th – 11th, 2016, and will also be exhibiting at Booth 606. Wendy Chung, M.D. Ph.D., Associate Professor of Pediatrics and Medicine, Columbia University and Chief Scientific Officer, GeneDx, will participate in the […]

Study Demonstrates OPKO’s 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer

4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announced today the results of a study for the 4Kscore® Test’s clinical utility in reducing the number of prostate biopsies performed, while increasing the probability of detecting aggressive prostate cancer […]

OPKO’s GeneDx to Present at Personalized Medicine World Conference

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that Marc D. Grodman, MD, Chief Executive Officer of its BioReference/GeneDx subsidiaries, will speak at this year’s Personalized Medicine World Conference, Silicon Valley. Dr. Grodman’s Presentation, titled “New Model of Clinical Genomics Collaboration”, will highlight a unique partnership between GeneDx and health systems to provide a complete genomic solution that facilitates improved […]

OPKO’s GeneDx Study of More Than 10,000 Individuals Tested with Multigene NGS Hereditary Cancer Panel Reveals New Risks

Largest Published Study to Date Supports Testing Changes and Development of New Treatment Options MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) through its subsidiary GeneDx, today announced results from the largest published study to date of patients who received hereditary genetic testing with Next Generation Sequencing (NGS) cancer panels. The study, “Pathogenic and Likely Pathogenic Variant Prevalence […]

OPKO’s GeneDx Subsidiary and North Shore-LIJ Health System Form Strategic Alliance for Genetic Testing

MIAMI, Dec. 14, 2015 /PRNewswire/ — The North Shore-LIJ Health System and OPKO Health, Inc. (NYSE: OPK) have formed a novel strategic alliance to provide genomic testing, molecular diagnostic testing and ancillary support services such as genetic counseling.  The scope of testing will cover all genetic disorders, including prenatal screening, pediatric and postnatal diagnosis, assessing risk for inherited cancer, and testing […]

Powered by GlobalLink OneLink Software